Lawmaker Urges FDA Not To Allow Off-Label Loophole

Law360, New York (November 30, 2007, 12:00 AM EST) -- The chair of the U.S. House of Representatives Oversight Committee sent a letter to the U.S. Food and Drug Administration Friday, urging the agency to rethink a recent internal draft guidance that would allow drug companies to promote drugs and devices for off-label use without FDA approval.

In his letter to FDA Commissioner Andrew C. von Eschenbach, Rep. Henry Waxman (D-Calif.) called the agency’s October draft guidance “ill-advised” and claimed it would “carve a large loophole in the law” by allowing drug and device manufacturers to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.